๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts

โœ Scribed by Edward Alabraba; Peter Nightingale; Bridget Gunson; Stefan Hubscher; Simon Olliff; Darius Mirza; James Neuberger


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
497 KB
Volume
15
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

โœฆ Synopsis


Previously, we have found that the absence of the colon after liver transplantation (LT) protects the patient from recurrent primary sclerosing cholangitis (rPSC). As our previous observation has not been confirmed in other series, we have reviewed our cohort of patients grafted for primary sclerosing cholangitis (PSC) with greater numbers and longer follow-up to reassess the rate, consequences, and risk factors for rPSC. We collected data on patients who underwent LT for PSC between January 1986 and April 2006. Data were collected for cytomegalovirus status, inflammatory bowel disease status, time of colectomy, type of colectomy, donor-recipient gender mismatch, recipient sex, extended donor criteria (EDC), and donor risk index. Accepted criteria were used to diagnose rPSC. Of a total of 230 consecutive adult patients, 61 (27%) underwent colectomy pre-/peri-LT, and 54 (23.5%) developed rPSC at a median of 4.6 (range, 0.5-12.9) years post-LT. A total of 263 deceased donor grafts were used, and 73 were EDC grafts. A diagnosis of rPSC was made in 61 of the 263 grafts (23%). The recurrence-free patient survival was significantly better (P ฯฝ 0.05) in patients who underwent pre-/peri-LT colectomy and in those with non-EDC grafts. In conclusion, in this larger cohort of 230 patients and with longer follow-up of 82.5 (range, 0.0-238.6) months [in comparison with the previous report of 152 recipients with a follow-up of 52.8 (range, 1-146) months], we have shown that colectomy remains a significant risk factor for rPSC and that colectomy before and during initial LT for PSC confers a protective effect against rPSC in subsequent graft(s). Moreover, we have shown that EDC grafts are also a significant risk factor for rPSC.


๐Ÿ“œ SIMILAR VOLUMES


Risk factors for recurrence of primary s
โœ Evangelos Cholongitas; Vibhakorn Shusang; George V. Papatheodoridis; Laura Marel ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 94 KB ๐Ÿ‘ 2 views

Liver transplantation (LT) is the only therapeutic option for end-stage primary sclerosing cholangitis (PSC), but PSC can recur (rPSC) in some patients after LT. The aim of our study was to evaluate the risk factors associated with rPSC. Between 1989 and 2004, 69 patients receiving transplantation f

Risk factors for recurrence of primary s
โœ Jacob Alexander; James D. Lord; Matthew M. Yeh; Carlos Cuevas; Ramasamy Bakthava ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 123 KB ๐Ÿ‘ 2 views

Orthotopic liver transplantation (OLT) is the only effective treatment for end-stage liver disease due to primary sclerosing cholangitis (PSC). Recurrence of PSC has recently emerged as a leading cause of allograft failure in the long term. There is limited data on risk factors for recurrence of PSC

Reply: The urgent need for evaluating re
โœ Edward Biobele Alabraba; Darius Mirza; James Neuberger ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 38 KB

We thank Tamura et al. 1 for their thought-provoking letter indicating that there are indeed still a lot of questions to be answered about the recurrence of primary sclerosing cholangitis (PSC). They suggested that a comparison of risk factors and rates of recurrence in living and deceased donor gra

Features of autoimmune hepatitis in prim
โœ K M Boberg; O Fausa; T Haaland; E Holter; O J Mellbye; A Spurkland; E Schrumpf ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 175 KB ๐Ÿ‘ 2 views

Overlapping features between primary sclerosing cholangitis (PSC and autoimmune hepatitis (AIH) have previously been noted. To assess systematically similarities between these disorders, we have evaluated 114 PSC patients (36 women; 78 men), all confirmed by endoscopic retrograde cholangiography (ER

Waitlist survival of patients with prima
โœ David Goldberg; Benjamin French; Arwin Thomasson; K. Rajender Reddy; Scott D. Ha ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 140 KB ๐Ÿ‘ 1 views

The ability of the Model for End-Stage Liver Disease (MELD) score to capture the urgency of transplantation may not be generalizable to patients with primary sclerosing cholangitis (PSC) because these patients face unique risks of death or removal from the liver transplant waitlist due to disease-sp